Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Medical Research Journal
MENU
Shortcuts Submit an article Author Guidelines Reviewers 2023 Focus and Scope

open access

Vol 7, No 2 (2022)
Original article
Published online: 2022-06-17
View PDF Download PDF file
Get Citation

Assessment of the chemerin, IL-6, and IL-23 correlations and their impact on CRC progression: An observational study

Julia Robotycka1, Sylwia Mielcarska1, Miriam Dawidowicz2, Agnieszka Kula2, Błażej Ochman1, Bogusława Strzałkowska1, Tomasz Niebudek1, Dariusz Waniczek2, Elżbieta Świętochowska1
DOI: 10.5603/MRJ.a2022.0026
·
Medical Research Journal 2022;7(2):157-163.
Affiliations
  1. Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland
  2. Department of Oncological Surgery, Faculty of Medical University of Silesia, Katowice, Poland

open access

Vol 7, No 2 (2022)
ORIGINAL ARTICLES
Published online: 2022-06-17

Abstract

Introduction: The role of proinflammatory cytokines is said to be crucial in the development of colorectal cancer (CRC). IL-6, IL-23, and chemerin have all been proven to take part in tumor growth and progression. Aim of the study: to determine the level of chemerin and the concentrations of interleukin-6 (IL-6) and interleukin- 23 (IL-23) in the tumor and margin specimens of CRC in relation to histological grade and TNM staging. Material and methods: The study involved 49 samples of tumor and margin tissues obtained from CRC patients. To assess the concentration of chemerin, IL-6, and IL-23, commercially available enzyme-linked immunosorbent assay (ELISA) kits were used. Results: There was no difference in chemerin concentration between the tumor and margin. We found significantly increased levels of IL-6 in tumor tissue compared to margin tissue and higher concentrations of IL-23 in margin tissue than in tumor tissue. Tumor levels of chemerin were significantly correlated with those of IL-23, while its margin concentrations were associated with margin concentrations of IL-6. Additionally, tumor levels of IL-23 were positively correlated with margin levels of IL-6. Conclusions: Chemerin might play an important role in CRC progression through its association with cytokine expression. More studies are needed to investigate the possible role of IL-6, IL-23, and chemerin as potential markers in the development of CRC.

Abstract

Introduction: The role of proinflammatory cytokines is said to be crucial in the development of colorectal cancer (CRC). IL-6, IL-23, and chemerin have all been proven to take part in tumor growth and progression. Aim of the study: to determine the level of chemerin and the concentrations of interleukin-6 (IL-6) and interleukin- 23 (IL-23) in the tumor and margin specimens of CRC in relation to histological grade and TNM staging. Material and methods: The study involved 49 samples of tumor and margin tissues obtained from CRC patients. To assess the concentration of chemerin, IL-6, and IL-23, commercially available enzyme-linked immunosorbent assay (ELISA) kits were used. Results: There was no difference in chemerin concentration between the tumor and margin. We found significantly increased levels of IL-6 in tumor tissue compared to margin tissue and higher concentrations of IL-23 in margin tissue than in tumor tissue. Tumor levels of chemerin were significantly correlated with those of IL-23, while its margin concentrations were associated with margin concentrations of IL-6. Additionally, tumor levels of IL-23 were positively correlated with margin levels of IL-6. Conclusions: Chemerin might play an important role in CRC progression through its association with cytokine expression. More studies are needed to investigate the possible role of IL-6, IL-23, and chemerin as potential markers in the development of CRC.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

Chemerin, Interleukin-6 (IL-6), Interleukin-23 (IL-23), Colorectal Cancer (CRC)

About this article
Title

Assessment of the chemerin, IL-6, and IL-23 correlations and their impact on CRC progression: An observational study

Journal

Medical Research Journal

Issue

Vol 7, No 2 (2022)

Article type

Original article

Pages

157-163

Published online

2022-06-17

Page views

4227

Article views/downloads

335

DOI

10.5603/MRJ.a2022.0026

Bibliographic record

Medical Research Journal 2022;7(2):157-163.

Keywords

Chemerin
Interleukin-6 (IL-6)
Interleukin-23 (IL-23)
Colorectal Cancer (CRC)

Authors

Julia Robotycka
Sylwia Mielcarska
Miriam Dawidowicz
Agnieszka Kula
Błażej Ochman
Bogusława Strzałkowska
Tomasz Niebudek
Dariusz Waniczek
Elżbieta Świętochowska

References (30)
  1. Zeng J, Tang ZH, Liu S, et al. Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World J Gastroenterol. 2017; 23(10): 1780–1786.
    CrossRefPubMed
  2. World Cancer Research Fund. Worldwide cancer data. https://www.wcrf.org/cancer-trends/worldwide-cancer-data/ (9.05.2022).
  3. Centers for Disease Control and Prevention. An Update on Cancer Deaths in the United States.: Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, Division of Cancer Prevention and Control; 2022.
  4. Akimoto N, Ugai T, Zhong R, et al. Rising incidence of early-onset colorectal cancer - a call to action. Nat Rev Clin Oncol. 2021; 18(4): 230–243.
    CrossRefPubMed
  5. Jasperson K, Tuohy T, Neklason D, et al. Hereditary and Familial Colon Cancer. Gastroenterology. 2010; 138(6): 2044–2058.
    CrossRef
  6. Thanikachalam K, Khan G. Colorectal Cancer and Nutrition. Nutrients. 2019; 11(1).
    CrossRefPubMed
  7. Roguska J, Zubkiewicz-Kucharska A. Chemerin as an early marker of metabolic syndrome. Pediatric Endocrinology Diabetes and Metabolism. 2018; 24(1): 45–51.
    CrossRef
  8. Helfer G, Wu QF. Chemerin: a multifaceted adipokine involved in metabolic disorders. J Endocrinol. 2018; 238(2): R79–R94.
    CrossRefPubMed
  9. Eichelmann F, Schulze MB, Wittenbecher C, et al. Association of chemerin plasma concentration with risk of colorectal cancer. JAMA Netw Open. 2019; 2(3): e190896.
    CrossRefPubMed
  10. Komoda H, Tanaka Y, Honda M, et al. Interleukin-6 levels in colorectal cancer tissues. World J Surg. 1998; 22(8): 895–898.
    CrossRefPubMed
  11. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014; 2(4): 288–294.
    CrossRefPubMed
  12. Waldner MJ, Foersch S, Neurath MF. Interleukin-6 - a key regulator of colorectal cancer development. Int J Biol Sci. 2012; 8(9): 1248–1253.
    CrossRefPubMed
  13. Lan F, Zhang Le, Wu J, et al. IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma. Int J Colorectal Dis. 2011; 26(12): 1511–1518.
    CrossRefPubMed
  14. Adamo V, Franchina T, Minciullo PL, et al. Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. J Cell Physiol. 2011; 226(11): 3032–3034.
    CrossRefPubMed
  15. Yan J, Smyth MJ, Teng MWL. Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer. Cold Spring Harb Perspect Biol. 2018; 10(7).
    CrossRefPubMed
  16. Alkady MM, Abdel-Messeih PL, Nosseir NM. Assessment of serum levels of the adipocytokine chemerin in colorectal cancer patients. J Med Biochem. 2018; 37(3): 313–319.
    CrossRefPubMed
  17. Chonov DC, Ignatova MM, Ananiev JR, et al. IL-6 activities in the tumour microenvironment. Part 1. Open Access Maced J Med Sci. 2019; 7(14): 2391–2398.
    CrossRefPubMed
  18. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer. 1999; 85(12): 2526–2531, doi: 10.1002/(sici)1097-0142(19990615)85:12<2526::aid-cncr6>3.0.co;2-3.
  19. Lo CH, Lee SC, Wu PY, et al. Antitumor and antimetastatic activity of IL-23. J Immunol. 2003; 171(2): 600–607.
    CrossRefPubMed
  20. Suzuki H, Ogawa H, Miura K, et al. IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma. Oncol Lett. 2012; 4(2): 199–204.
    CrossRefPubMed
  21. Ljujic B, Radosavljevic G, Jovanovic I, et al. Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma. Arch Med Res. 2010; 41(3): 182–189.
    CrossRefPubMed
  22. FM R, S H, MA Z, et al. Evaluation of expression pattern of vascular endothelial growth factor (VEGF) and interleukin-23 (IL-23) genes in human colorectal tumors. Journal of Molecular and Genetic Medicine. 2018; 12(1).
    CrossRef
  23. Wang J, Xu K, Wu J, et al. The changes of Th17 cells and the related cytokines in the progression of human colorectal cancers. BMC Cancer. 2012; 12: 418.
    CrossRefPubMed
  24. Kim DK, Oh SY, Kwon HC, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009; 9: 155.
    CrossRefPubMed
  25. Chung YC, Chaen YL, Hsu CP. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res. 2006; 26(5B): 3905–3911.
    PubMed
  26. Shiga K, Hara M, Nagasaki T, et al. Preoperative serum interleukin-6 is a potential prognostic factor for colorectal cancer, including stage II patients. Gastroenterol Res Pract. 2016; 2016: 9701574.
    CrossRefPubMed
  27. Stanilov N, Miteva L, Deliysky T, et al. Advanced colorectal cancer is associated with enhanced IL-23 and IL-10 serum levels. Laboratory Medicine. 2010; 41(3): 159–163.
    CrossRef
  28. Zhang Le, Li J, Li Li, et al. IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway. Carcinogenesis. 2014; 35(6): 1330–1340.
    CrossRefPubMed
  29. Wang K, Karin M. The IL-23 to IL-17 cascade inflammation-related cancers. Clin Exp Rheumatol. 2015; 33(Suppl 92): S87–90.
    PubMed
  30. Elessawi DF, Alkady MM, Ibrahim IM. Diagnostic and prognostic value of serum IL-23 in colorectal cancer. Arab J Gastroenterol. 2019; 20(2): 65–68.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl